

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220
P03505	ACTION as well as, where applicable, item 5 below.	
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US2005/009684	22/03/2005	31/03/2004
Applicant		
BAUSCH & LOMB INCORPORATE		
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Aut ansmitted to the International Bureau.	nority and is transmitted to the applicant
This International Search Report consists	of a total of sheets.	
X It is also accompanied by	a copy of each prior art document cited in this	report.
Basis of the report		
	international search was carried out on the ba less otherwise indicated under this item.	sis of the international application in the
The international this Authority (Ru		lation of the international application furnished to
. b. With regard to any nucle	otide and/or amino acid sequence disclosed	in the international application, see Box No. I.
2. Certain claims were fou	nd unsearchable (See Box II).	
3. Unity of invention is lac	king (see Box III).	
4. With regard to the title ,		
X the text is approved as su	ubmitted by the applicant.	
the text has been establis	shed by this Authority to read as follows:	
	•	
		•
5. With regard to the abstract,		
	ubmitted by the applicant.	
	shed, according to Rule 38.2(b), by this Autho om the date of mailing of this international sea	rity as it appears in Box No. IV. The applicant rch report, submit comments to this Authority.
6. With regard to the drawings,		
	published with the abstract is Figure No. $\underline{}$	a
X as suggested by	the applicant.	
as selected by th	is Authority, because the applicant failed to su	uggest a figure.
	is Authority, because this figure better charac	terizes the invention.
b none of the figures is to t	pe published with the abstract.	

International application No.

INTERNATIONAL SEARCH REPORT

PCT/US2005/009684

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

A device (10) for injecting an intraocular lens (IOL) into an eye, the device ha ving an injector body (12) including a lumen (14) and an open tip (18a) wherethr ough the IOL is expressed from the device. An IOL loading bay (26) is located in the passageway wherein the IOL (30) is positioned and compressed. The injector tip is dimensioned to allow the surgeon to choose an insertion depth between fir st, second and third transition points defined on the tip, the first and second transition points having a larger diameter than the third transition point which is located closer to the open tend of the tip. If the surgeon wishes to insert through a very small incision size (e.g., about 2.4mm), the surgeon will insert the tip only up to the third transition point. The injector is stable during delivery of the IOL therethrough due to a spreading of the tip within the eye.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US2005/009684

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61F2/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{A61F} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/64147 A (STAAR SURGICAL COMPANY, INC.) 7 September 2001 (2001-09-07) page 2, line 13 - line 15	1-12
	page 10, line 4 - line 14 page 20, line 7 - line 16; claim 1; figures 1,15,18	
Y.	EP 0 270 257 A (THE COOPER COMPANIES, INC.) 8 June 1988 (1988-06-08)	1
A	column 6, line 24 - line 35 column 7, line 27 - line 31 column 8, line 37 - column 9, line 4; claim 7; figures 5,31,33,36,41	2–12
Υ	US 2002/193805 A1 (ALLERGAN SALES, INC.) 19 December 2002 (2002-12-19)	1
Α	page 3, paragraph 36; claim 3; figures 3B,4A	2-12

· · · · · · · · · · · · · · · · · · ·	
X Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
10 August 2005	19/08/2005
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Riiswiik	Authorized officer
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Merté, B

1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/009684

	ion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	 	Relevant to claim No.
A	WO 03/077805 A (ADVANCED MEDICAL OPTICS, INC; OTT, ROBERT, D) 25 September 2003 (2003-09-25) abstract; figure 4		1-12
1		·	
·			
·		*.*	

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No PCT/US2005/009684

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0164147	Α	07-09-2001	US AU WO	6387101 B1 3991001 A 0164147 A1	14-05-2002 12-09-2001 07-09-2001
EP 0270257	A	08-06-1988	US AU AU EP JP	4919130 A 608548 B2 8099887 A 0270257 A1 63197453 A	24-04-1990 11-04-1991 12-05-1988 08-06-1988 16-08-1988
US 2002193805	A1	19-12-2002	US EP JP WO US	6447520 B1 1370198 A2 2004524105 T 02074208 A2 2002193876 A1	10-09-2002 17-12-2003 12-08-2004 26-09-2002 19-12-2002
WO 03077805	Α	25-09-2003	US AU EP WO	2003176870 A1 2003214150 A1 1513473 A1 03077805 A1	18-09-2003 29-09-2003 16-03-2005 25-09-2003

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International filing date (day/month/year) Priority date (day/month/year) International application No. 22.03.2005 31.03.2004 PCT/US2005/009684 International Patent Classification (IPC) or both national classification and IPC A61F2/16 Applicant **BAUSCH & LOMB INCORPORATED** This opinion contains indications relating to the following items: Box No. I Basis of the opinion ☐ Box No. II Priority ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited Box No. VII Certain defects in the international application ☐ Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA: **Authorized Officer** European Patent Office D-80298 Munich Merté, B

Telephone No. +49 89 2399-2851

Tel. +49 89 2399 - 0 Tx: 523656 epmu d

Fax: +49 89 2399 - 4465

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2005/009684

_	Box N	p. I Basis of the opinion
1.	With re	gard to the language , this opinion has been established on the basis of the international application in guage in which it was filed, unless otherwise indicated under this item.
	lai	is opinion has been established on the basis of a translation from the original language into the following nguage , which is the language of a translation furnished for the purposes of international search nder Rules 12.3 and 23.1(b)).
2.	With renecess	egard to any nucleotide and/or amino acid sequence disclosed in the international application and sary to the claimed invention, this opinion has been established on the basis of:
	a. type	of material:
	. 🗆	a sequence listing
		table(s) related to the sequence listing
	b. form	nat of material:
		in written format
		in computer readable form
	c. time	of filing/furnishing:
		contained in the international application as filed.
		filed together with the international application in computer readable form.
	. 🗆	furnished subsequently to this Authority for the purposes of search.
3.	ha Co	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto as been filed or furnished, the required statements that the information in the subsequent or additional opies is identical to that in the application as filed or does not go beyond the application as filed, as opropriate, were furnished.

4. Additional comments:

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No: Claims

Inventive step (IS)

Yes: Claims

Claims

1-12

1

Industrial applicability (IA)

Yes: Claims

1-12

Claims No:

2. Citations and explanations

see separate sheet

Certain defects in the international application Box No. VII

The following defects in the form or contents of the international application have been noted:

see separate sheet

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

V.1 Closest State of the Art:

In the technical field of injectors for delivering a foldable intraocular lens (IOL) into an eye, the closest prior art is considered to be represented by the document

D1: WO 01/64147 A (STAAR SURGICAL COMPANY, INC.) 7 September 2001 (2001-09-07)

that discloses an IOL injector tip for delivering a foldable IOL into an eye (D1: p. 20, I. 10-11), said tip comprising first (Fig. 15, reference numeral 22), second (rn 106), third and fourth contiguous segments (tip portion rn 108, composed of rn 112 and 114; col. 20, I. 12-16), said first segment extending from the injector body (Fig. 1, rn 16) and said fourth segment terminating at an open end wherethrough the IOL exits the injector (cl. 1; Fig. 18), and further including at least one slot extending through said third and fourth segments to said open end (p. 10, I. 10-11); whereby said tip may be inserted through an incision in an eye up to the juncture of said third and fourth segments (p. 10, I. 5-7) whereby said fourth segment may spread open about said slots upon the IOL passing therethrough (p. 10, I. 1-13), said fourth segment retracting to its original diameter once the IOL has exited the injector tip into the eye ("prior to complete release": p. 10, I. 13-14).

V.2 Lack of Novelty [Article 33(2) PCT]:

From the above follows that the subject-matter of **claim 1** is entirely anticipated by document **D1** as representative for the prior art.

V.3 Lack of Inventive Activity [Article 33(3) PCT]:

If not even explicitly known from **D1**, the dimensions and relative positions of the tapering and cylindrical sections within the generally tapering dispenser tip (subject-matters of **claims 2-12**) are at least merely examples of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill, in order to solve the problem of allowing a deformed IOL to be expelled in a predictable manner.

It is to be noted that the principle of IOL delivering tip having a slot or four tapering sections is generally known in the art, see e.g.

Figs. 31, 33, and 36 of

D2: EP-A-0 270 257 (THE COOPER COMPANIES, INC.) 8 June 1988 (1988-06-08) or **Figs. 3B** and **4A** of

D3: US 2002/193805 A1 (ALLERGAN SALES, INC.) 19 December 2002 (2002-12-19)

that discloses an IOL injector cartridge.

Re Item VII

Certain defects in the international application

- The independent claims should be drafted in the two-part format according to **Rule 6.3(b) PCT.**
- All features of the claims should be identified by reference signs placed in parentheses [Rule 6.2(b) PCT].
- The documents **D1** and **D2** should be acknowledged in the description [**Rule** 5.1(a)(ii) **PCT**].
- All documents cited in the description should be identified by their publication numbers for better accessibility to the public, see **p. 8**